Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Leqembi Autoinjector Advances with FDA Review for Alzheimer’s Treatment

Fineline Cube Jan 14, 2025

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...

Company Deals

Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463

Fineline Cube Jan 14, 2025

US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly...

Company Deals

Cornerstone Robotics Raises $68.2M in Series C to Advance Surgical Robots

Fineline Cube Jan 14, 2025

Cornerstone Robotics, an innovative surgical robot developer based in Shenzhen, has reportedly raised over RMB...

Company Medical Device

MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer

Fineline Cube Jan 14, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd has announced that it has received a...

Company Medical Device

Medtronic’s BrainSense Technologies Win EU, UK CE Mark for Parkinson’s Treatment

Fineline Cube Jan 14, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that it has received CE (Conformité Européenne) Mark...

Company Deals

Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline

Fineline Cube Jan 14, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100%...

Company Drug

Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA

Fineline Cube Jan 14, 2025

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...

Company Drug

Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China

Fineline Cube Jan 14, 2025

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...

Company Drug

Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors

Fineline Cube Jan 14, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals Drug

Zhaoke Ophthalmology Partners with AFT for Brimochol PF Distribution in ANZ

Fineline Cube Jan 14, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a strategic distribution and supply agreement with...

Company Drug

Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...

Company Deals

Neo Modulus Secures $40.9M Series C Funding for Regenerative Medical Devices

Fineline Cube Jan 14, 2025

Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., a prominent developer of regenerative implantable medical devices...

Company Deals

MediLink Therapeutics and AstraZeneca Collaborate on YL201 and Imfinzi Combo for Solid Tumors

Fineline Cube Jan 14, 2025

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced a clinical cooperation agreement with...

Company Deals

Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500

Fineline Cube Jan 14, 2025

China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...

Company Drug

CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment

Fineline Cube Jan 14, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...

Company Deals

3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303

Fineline Cube Jan 14, 2025

China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...

Company Deals Medical Device

CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion

Fineline Cube Jan 14, 2025

CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...

Company Drug

JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE

Fineline Cube Jan 13, 2025

China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...

Company Drug

CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval

Fineline Cube Jan 13, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...

Company Deals

Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership

Fineline Cube Jan 13, 2025

China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...

Posts pagination

1 … 279 280 281 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.